Viewing Study NCT05384756


Ignite Creation Date: 2025-12-24 @ 11:24 PM
Ignite Modification Date: 2026-05-12 @ 2:44 PM
Study NCT ID: NCT05384756
Status: RECRUITING
Last Update Posted: 2024-12-31
First Post: 2022-05-03
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: TMLI and Alemtuzumab for Treatment of Sickle Cell Disease
Sponsor: City of Hope Medical Center
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Sickle Cell Disease View
Keywords: